Southgate T D, Stone D, Williams J C, Lowenstein P R, Castro M G
Molecular Medicine and Gene Therapy Unit, School of Medicine, University of Manchester, Manchester M13 9PT, United Kingdom.
Endocrinology. 2001 Jan;142(1):464-76. doi: 10.1210/endo.142.1.7898.
Adenoviral vectors have been identified as useful tools for gene transfer to the pituitary gland with the aim of providing therapeutic treatments for pituitary diseases. Although successful adenovirus-mediated gene transfer to the pituitary has been shown, the duration of transgene expression, local immune responses and consequences on circulating pituitary hormone levels have not been investigated. These are critical not only for the successful implementation of these gene transfer techniques both for physiological and/or therapeutic applications but also for assessing the safety of these approaches. We have therefore assessed duration and levels of transgene expression 3 days, 14 days, 1, 2, and 3 months after delivery of adenoviruses expressing herpes simplex virus type 1 thymidine kinase (HSV1-TK), under the control of the major immediate early human cytomegalovirus (RAd-hCMV/TK) or human PRL (RAd-hPrl/TK) promoters, to the anterior pituitary (AP) gland in situ. The presence of vector genome and cellular immune infiltrates within the AP gland were also studied along with the levels of circulating anti-adenovirus neutralizing antibodies and AP hormones in sera. Ubiquitous or cell-type specific expression of HSV1-TK within the AP gland was seen from RAd-hCMV/TK and RAd-hPrl/TK respectively at all time points, although a reduction in expression was seen over time. PCR amplification of HSV1-TK specific sequences showed the persistence of adenoviral genomes for up to 3 months. Analysis of the AP showed the presence of a virus-induced inflammation that peaked around day 14 and was resolved between 2-3 months. ED1-positive macrophages, CD8-positive T-cells and CD161-positive NK cells were identified up to 1 month after virus administration. A virus-induced humoral immune response was also present as anti-adenovirus neutralizing antibodies were detected from 14 days after virus administration. Levels of circulating pituitary hormones were unaffected by virus administration with the exception of the stress hormone ACTH which was increased at 3 days but normalized by 14 days. In conclusion, our data indicates that adenovirus-mediated delivery to the AP gland in situ may be a useful tool for the treatment of pituitary diseases as no major cytotoxicity or disruption of AP hormonal functions are seen. Despite of this, further developments to this approach still need to be made to combat the reduced transgene expression seen over time and the induction of virus-induced immune responses.
腺病毒载体已被确定为将基因导入垂体的有用工具,旨在为垂体疾病提供治疗方法。尽管已证明腺病毒介导的基因成功导入垂体,但转基因表达的持续时间、局部免疫反应以及对循环垂体激素水平的影响尚未得到研究。这些不仅对于这些基因转移技术在生理和/或治疗应用中的成功实施至关重要,而且对于评估这些方法的安全性也至关重要。因此,我们评估了在人巨细胞病毒主要立即早期启动子(RAd-hCMV/TK)或人催乳素启动子(RAd-hPrl/TK)控制下,表达单纯疱疹病毒1型胸苷激酶(HSV1-TK)的腺病毒原位导入垂体前叶(AP)后3天、14天、1个月、2个月和3个月时转基因表达的持续时间和水平。还研究了AP腺体内载体基因组和细胞免疫浸润的情况,以及血清中循环抗腺病毒中和抗体和AP激素的水平。在所有时间点,分别从RAd-hCMV/TK和RAd-hPrl/TK中观察到HSV1-TK在AP腺体内的普遍或细胞类型特异性表达,尽管随着时间的推移表达有所下降。HSV1-TK特异性序列的PCR扩增显示腺病毒基因组持续存在长达3个月。对AP的分析显示存在病毒诱导的炎症,在第14天左右达到峰值,并在2至3个月内消退。在病毒给药后1个月内均可识别出ED1阳性巨噬细胞、CD8阳性T细胞和CD161阳性NK细胞。由于在病毒给药后14天检测到抗腺病毒中和抗体,因此也存在病毒诱导的体液免疫反应。除应激激素促肾上腺皮质激素(ACTH)在3天时升高但在14天时恢复正常外,循环垂体激素水平不受病毒给药的影响。总之,我们的数据表明,腺病毒介导的原位导入AP腺可能是治疗垂体疾病的有用工具,因为未观察到主要的细胞毒性或AP激素功能的破坏。尽管如此,仍需要对该方法进行进一步改进,以应对随着时间推移出现的转基因表达降低和病毒诱导的免疫反应。